Q-omics provides the consensus-scored TUBA3E profile across patient tissues and cancer cell-line models. TUBA3E expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TUBA3E is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, TUBA3E RNA expression shows 11,075 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, and THYM as cancer lineages where TUBA3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA3E survival associations across molecular data types. TUBA3E RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA3E RNA expression–survival associations across cancer types. High TUBA3E expression shows unfavorable associations in THCA, LIHC, LGG and BLCA, but favorable associations in BRCA and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TUBA3E RNA expression.
This table summarizes TUBA3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TUBA3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA3E shows lower tumor expression in UCEC and THCA and higher tumor expression in BRCA, KIRC, COAD and LUSC. The BRCA box plot shows higher TUBA3E RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p < 0.001).
This table shows molecular features associated with TUBA3E in patient tissues and cancer cell lines. In patient samples, TUBA3E shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
